Eterna Therapeutics Inc Ordinary Shares ERNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ERNA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.74
- Day Range
- $1.58–1.89
- 52-Week Range
- $0.84–3.45
- Bid/Ask
- $1.55 / $1.77
- Market Cap
- $9.68 Mil
- Volume/Avg
- 15,069 / 8,336
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 135.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.eternatx.com
Valuation
|
Metric
|
ERNA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.21 |
Price/Sales | 135.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ERNA
|
|---|---|
Quick Ratio | 1.22 |
Current Ratio | 1.46 |
Interest Coverage | −34.52 |
Quick Ratio
ERNA
Profitability
|
Metric
|
ERNA
|
|---|---|
Return on Assets (Normalized) | −54.46% |
Return on Equity (Normalized) | −347.05% |
Return on Invested Capital (Normalized) | −66.77% |
Return on Assets
ERNA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pryvcrtggb | Hssw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yblhsndl | Qxtgyrs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gbgrswgx | Zwvwdp | $97.8 Bil | |
MRNA
| Moderna Inc | Hgmtrvwy | Xyqy | $41.3 Bil | |
ARGX
| argenx SE ADR | Qwwjvtr | Tqsq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dcdcymbz | Pprs | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vzqdqdwt | Wvjhrkd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jwptzff | Grrqvgn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wtzfjsrdp | Jzztgw | $12.5 Bil | |
INCY
| Incyte Corp | Wtzjpfhk | Jttlv | $11.6 Bil |